PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Clinical trials for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) trials appear
Sign up with your email to follow new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat cancers: drug targets RAS mutations
Disease control Not yet recruitingThis study tests a new drug called BPI-572270 in 120 adults with advanced solid tumors (lung, colon, or pancreatic cancer) that have specific RAS gene mutations. The goal is to see if the drug is safe and can shrink or control the tumors. Participants must have already tried stan…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 10:10 UTC
-
New catheter method aims to boost chemo power against tough pancreatic cancer
Disease control Not yet recruitingThis early-stage trial tests whether delivering a standard chemotherapy drug (gemcitabine) directly into the blood vessels feeding a pancreatic tumor can make it easier to remove the cancer completely during surgery. Ten people with borderline resectable pancreatic cancer will re…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: University of Vermont • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New combo therapy targets tough gut cancers in major trial
Disease control Not yet recruitingThis study tests a new drug called SSGJ-706 combined with standard treatments for people with advanced stomach, colon, pancreatic, or esophageal cancers that cannot be removed by surgery. The goal is to see if the combination is safe and helps shrink or control tumors. About 300 …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for tough pancreatic cancer: targeted drug trial launches
Disease control Not yet recruitingThis study tests a new drug called HLX43 in 100 people with advanced pancreatic cancer that has not responded to other treatments. The drug targets a protein on cancer cells to help the immune system attack them. The goal is to find the best dose and see if it can shrink tumors o…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
Scientists hunt for clues to personalize pancreatic cancer therapy
Knowledge-focused Not yet recruitingThis study aims to find biological markers in blood and stool that can predict how well patients with advanced pancreatic cancer will respond to treatment. Researchers will analyze samples from 140 participants to develop a personalized treatment plan. The goal is to improve outc…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: Chang Gung Memorial Hospital • Aim: Knowledge-focused
Last updated May 17, 2026 10:07 UTC
-
Bile drain before pancreatic surgery: help or hindrance?
Knowledge-focused Not yet recruitingThis study looks at whether draining bile before surgery for pancreatic cancer changes how the tumor behaves or how long patients live. Researchers will review medical records of 90 adults who had their pancreatic tumor removed over 8 years. No new treatments or procedures are gi…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: East Lancashire Hospitals NHS Trust • Aim: Knowledge-focused
Last updated May 17, 2026 10:07 UTC
-
Simple hand squeeze test may reveal hidden clues in pancreatic cancer
Knowledge-focused Not yet recruitingThis study looks at whether measuring hand grip strength in adults with pancreatic cancer can give doctors useful information about how the disease and treatment are affecting the body. About 50 participants will squeeze a handheld device during regular clinic visits and fill out…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: NA • Sponsor: British Columbia Cancer Agency • Aim: Knowledge-focused
Last updated May 15, 2026 11:57 UTC